MYC and cancer: Given most cancers have deregulated MYC expression, and as a consequence, BCL-2 pro-survival proteins are often also deregulated to counter the pro-apoptotic effect of high MYC expression, there is a strong rationale for co-targeting of MYC and BCL-2 proteins in many cancers (Figure 2).